- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01400308
Effectiveness of Two Protocols for Corporal Decolonization in Patients Colonized by Methicillin Resistant Staphylococcus Aureus (MRSA)
Clinical Trial to Compare the Effectiveness of Two Protocols for Corporal Decolonization in Patients Colonized by MRSA (Methicillin Resistant Staphylococcus Aureus)
Multicenter Clinical Trial, experimental, randomized and prospective study to determine the effectiveness of two protocols addressing the Corporal Decolonization in patients colonized by Methicillin Resistant Staphylococcus Aureus (MRSA).
PRIMARY END POINT The aim of this trial is to evaluate the effectiveness of the protocol Prontoderm® in the decolonization of MRSA patients, compared with the protocol of the "Consensus Document and GEIH-SEIMC SEMPSPH" (see attached extract from the document, Annex 7).
Prontoderm ® is a Class III Medical Device with CE mark owned by B.BRAUN Medical SA, and currently available in Spain for the same indications proposed in this trial.
Study Overview
Status
Intervention / Treatment
Detailed Description
Design: Multicenter, experimental, randomized and prospective study. The patients were consecutively and alternately assigned to each comparison group. Randomization was assured by central randomization and the first patient to one of the groups and, from there, too centrally, back to each of the two groups.
Group A will be treated with the protocol described in the "Consensus document and GEIH-SEIMC SEMPSPH" Version 31/10/07, as shown listed in Table 4. It is a protocol of 5 days (nasal mupirocin and chlorhexidine, potentially plus systemic antibiotics and 7 days).
Group B will be treated with the protocol established for Prontoderm® for five days and eventually plus systemic antibiotics. Ensure the correct application of the treatments without interruption over the weekend indicated protocol.
Sample Calculation: The investigators propose an initial sample of 310 patients for a bilateral approach with a type I error α = 0.05 and β type II error of 20%.
Analysis:
Simple analysis and logistic regression (to adjust for risk factors, sources, concomitant therapy, etc) compared the frequency of decolonization of MRSA, according to sources.
Procedures: To collect information using a standardized form CRD in paper to all hospitals, indicating the parameters listed in this protocol and cultures to be done both baseline and monitoring cultures
DISEASE IN STUDY
This will be treated either or both of the following conditions:
MRSA Colonization: The presence of the organism in the flora of the patient, detected by positive culture for MRSA, and no diagnosis of infection.
MRSA infections: presence of the organism between the flora of the patient, detected by positive culture for MRSA, and the presence of MRSA infection diagnosed according to criteria EPINE 2009 (Annex 8).
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Barcelona, Spain, 08907
- Hospital Universitari de Bellvitge
-
Valencia, Spain, 46015
- Hospital Arnau de Vilanova
-
Valencia, Spain, 46010
- Hospital Clínic Universitari de Valencia.
-
-
Valencia
-
Elche, Valencia, Spain, 03203
- Hospital General Universitario de Elche.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- MRSA infected or colonized Patients
Exclusion Criteria:
Patients whose condition or treatment interferes with the proper implementation of the proposed protocols, such as:
- Patients admitted to the ICU
- Patients undergoing resuscitation
- Immobilized patients-avoiding their complete hygiene
- Patients carrying nasogastric tube
- Patients with tracheostomy and / or assisted mechanical ventilation
- Patients who are unable, neither they nor their representatives, to give valid informed consent.
- Patients whose discharged is planned before completing protocol
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Chlorhexidine + Mupirocin
Will be treated with the protocol described in the "Consensus document and GEIH-SEIMC SEMPSPH" Version 31/10/07, as shown listed in Table 4.
It is a protocol of 5 days (nasal mupirocin and chlorhexidine, potentially plus systemic antibiotics and 7 days).
|
Treatment after protocol described in the "Consensus document and GEIH-SEIMC SEMPSPH" Version 31/10/07.
It is a protocol of 5 days (nasal mupirocin and chlorhexidine, potentially plus systemic antibiotics and 7 days)
|
Experimental: Prontoderm
Will be treated with the protocol established for Prontoderm® for five days and eventually plus systemic antibiotics.
|
Treatment after protocol established for Prontoderm® for five days and eventually plus systemic antibiotics. Prontoderm® is a Class III medical device |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Decolonization of MRSA patients
Time Frame: Final treatment day + 4 (by second control sample)
|
The aim of this trial is to evaluate the effectiveness of the protocol "Prontoderm ® in the decolonization of MRSA patients", compared with the protocol of the "Consensus Document and GEIH-SEIMC SEMPSPH" Prontoderm ® is a Class III Medical Device with CE mark owned by B.BRAUN Medical SA, and currently available in Spain and all over Europe for the same indications proposed in this trial.
|
Final treatment day + 4 (by second control sample)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent of decolonization out of total by trained staff treated patients
Time Frame: Up to two years
|
For both arms, determine the importance of staff training and the proper procedure in the application of hygiene measures, by comparing trial outcomes with same centre historical outcomes regarding MRSA decolonization
|
Up to two years
|
Quantitative (0-10 scale) and qualitative (open questions) measure of the usability of experimental and control products by users
Time Frame: The fifth, final day of treatment
|
Measure of user satisfaction regarding the usability of the experimental product vs control, by self-administered questionnaire.
The fifth and final day of treatment the staff fills out a questionnaire that includes questions about product usability
|
The fifth, final day of treatment
|
Quantitative (0-10 scale) and qualitative (open questions) measure of the acceptance of experimental and control products by staff
Time Frame: The fifth, final day of treatment
|
Measure of user satisfaction regarding features of the experimental product vs control, by self-administered questionnaire.
The fifth and final day of treatment the staff fills out a questionnaire that includes questions about products' features
|
The fifth, final day of treatment
|
Quantitative (0-10 scale) and qualitative (open questions) measure of the organoleptic features of experimental and control products by patients
Time Frame: The fifth, final day of treatment
|
Measure of patient rating satisfaction regarding the organoleptic features of the experimental product vs control, by self-administered questionnaire.The fifth and final day of treatment the staff fills out a questionnaire that includes questions about product organoleptic features
|
The fifth, final day of treatment
|
Quantitative (0-10 scale) and qualitative (open questions) measure of the acceptance of experimental and control products by patient
Time Frame: The fifth, final day of treatment
|
Measure of patients' satisfaction regarding features of the experimental product vs control product, by self-administered questionnaire.
The fifth and final day of treatment the patient fills out a questionnaire that includes questions about product acceptance
|
The fifth, final day of treatment
|
Percent of decolonization in with Prontoderm® treated multiresistant colonizations decolonization for other multiresistant organisms (not MRSA)
Time Frame: After completation of treatment (5 days) two culture are done (2nd day and forth day after finishing) and colonizationd + resistances are mesured
|
Rate effectiveness of Prontoderm® for other multiresistant organisms (such as Acinetobacter, Pseudomonas, Vancomycin Resistant Enterococcus , E. Coli, Klebsiella and other Enterobacteriaceae producing ESBL). In the pretreatment culture not only MRSA but also other of the above mentioned bacteria can appear. After finishing treatment, the decolonization of these other bacteria will be assessed (effectiveness of product) |
After completation of treatment (5 days) two culture are done (2nd day and forth day after finishing) and colonizationd + resistances are mesured
|
Incidence and prevalence of multidrug resistant bacteria after experimental vs control treatment
Time Frame: After completation of treatment (5 days) two culture are done (2nd day and forth day after finishing) and colonizationd + resistances are mesured
|
To assess the difference in the appearance of multidrug resistance between both arms
|
After completation of treatment (5 days) two culture are done (2nd day and forth day after finishing) and colonizationd + resistances are mesured
|
Delta (decrease or increase) in MRSA epidemiology (incidence, prevalence) for the centre comparing the years before trial and after trial
Time Frame: Up to two years
|
Mesure of impact of the experimental protocol on the epidemiology by measuring the decrease or increase in MRSA epidemiology (incidence, prevalence) after applying the experimental protocol compared with historical figures from the center- in hospitals where there is a vigilance system for nosocomial infection
|
Up to two years
|
Assess the efficiency (economic impact) of the proposed protocol
Time Frame: Up to two years
|
Costs of both (experimental and control) treatments will be compared, considering not only price of products, but other MRSA treatment related resources such as staff time, isolation days, etc, to assess the efficiency, economic impact, of the proposed protocol with Prontoderm®, compared with control treatment.
|
Up to two years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Rafael Ortí, Dr., Responsible for Preventive Medicine Hospital Clínic Universitari de Valencia
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- OPM-G-H-0903
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on MRSA - Methicillin Resistant Staphylococcus Aureus Infection
-
CAMC Health SystemUnknownMRSA - Methicillin Resistant Staphylococcus Aureus InfectionUnited States
-
University of PennsylvaniaChildren's Hospital of Philadelphia; Milton S. Hershey Medical Center; Pennsylvania...CompletedMRSA - Methicillin Resistant Staphylococcus Aureus InfectionUnited States
-
Massachusetts General HospitalTerminatedMRSA - Methicillin Resistant Staphylococcus Aureus InfectionUnited States
-
Forest LaboratoriesCompletedStaphylococcus Aureus Bacteremia | Methicillin-resistant Staphylococcus Aureus (MRSA) BacteremiaUnited States
-
Washington University School of MedicineActive, not recruitingStaphylococcus Aureus | Skin and Subcutaneous Tissue Bacterial Infections | MRSA - Methicillin Resistant Staphylococcus Aureus InfectionUnited States
-
PfizerCompletedSkin/Soft Tissue Infections | Methicillin Resistant Staphylococcus Aureus (MRSA)United States, Spain, United Kingdom, Colombia, Italy, Chile, Argentina, Mexico, Belgium, Russian Federation, Brazil, Malaysia, Singapore, Portugal, South Africa, Venezuela
-
Ann & Robert H Lurie Children's Hospital of ChicagoTerminatedSkin Abscess | Abscess Soft Tissue | Methicillin-resistant Staphylococcus Aureus (MRSA) InfectionUnited States
-
Ohio State UniversityCompletedMethicillin-resistant Staphylococcus Aureus | Methicillin-Sensitive Staphylococcus Aureus InfectionUnited States
-
Tel-Aviv Sourasky Medical CenterUnknownMethicillin-Resistant Staphylococcus Aureus | ESBL InfectionIsrael
-
University of CalgaryCanadian Institutes of Health Research (CIHR); Alberta Heritage Foundation... and other collaboratorsCompletedClostridium Difficile Infection | Nosocomial Infection | Vancomycin Resistant Enterococci Infection | Methicillin Resistant Staphylococcus Aureus Infection (MRSA)Canada
Clinical Trials on Mupirocin + Chlorhexidin
-
Kwong Wah HospitalThe Hong Kong Society of NephrologyUnknownRate of Exit Site Infection | Rate of Atypical Mycobacterial Infection | Rate of Peritoneal DialysisHong Kong
-
University of Nove de JulhoCompletedRenal Insufficiency, Chronic | PhotochemotherapyBrazil
-
Reig Jofre GroupCompleted
-
US Department of Veterans AffairsUniversity of Michigan; Saint Joseph Mercy Health SystemCompleted
-
Jiangxi Provincial Cancer HospitalRecruitingQuality of Life | Nasopharyngeal Carcinoma | Bacterial Colonization | Radiation-induced Oral MucositisChina
-
Gundersen Lutheran Medical FoundationGundersen Lutheran Health SystemCompletedSurgical Site InfectionsUnited States
-
University Health Network, TorontoCompleted
-
University of ChicagoCompletedEndophthalmitis | Prophylaxis | Cataract SurgeryUnited States
-
Brooke Army Medical CenterGlaxoSmithKline; Becton, Dickinson and CompanyCompletedCellulitis | Folliculitis | Abscesses | Community-Acquired MRSA InfectionsUnited States
-
Mercy ResearchWithdrawnMethicillin-Resistant Staphylococcus Aureus